“There is good news and bad news about enrolling patients in clincal trials. First, the good news – 89 percent of all trials meet their enrollment goals. Now, the bad news – 48 percent of the trial sites miss enrollment targets and study timelines often slip, causing extensions that are nearly double the original duration in order to meet enrollment levels for all therapeutic areas.
This sobering finding was contained in the latest report from the Tufts Center for the Study of Drug Development, which examined patient recruitment and retention practices in clinical trials. The report suggests that drugmakers and contract research organizations may have difficulty because they rely on traditional approaches. The analysis was based on more than 150 clinical studies involving nearly 16,000 sites in different countries. “
Ed Silverman // January 15th, 2013 // 10:27 am-Pharmalot
“There is no relationship between false diagnosis and patient recuitment.”
“With enough patients there’s no end to the solid evidence based science we can accomplish.”